Champions Oncology, Inc. (CSBR) Earnings History
Net Loss30 years of earnings data (1996–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Champions Oncology, Inc. (CSBR) Earnings Overview
As of June 28, 2026, Champions Oncology, Inc. (CSBR) reported trailing twelve-month net income of -$2M, reflecting +161.1% year-over-year growth. The company earned $-0.16 per diluted share over the past four quarters, with a net profit margin of 8.3%.
Looking at the long-term picture, CSBR's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2025, representing a new all-time high.
Champions Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), CASI (-$49M net income, -137.6% margin), TPVG (-$12M net income, 50.6% margin), CSBR has comparable earnings metrics. Compare CSBR vs IMVT →
CSBR Earnings vs Peers
Earnings metrics vs comparable public companies
CSBR Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5M | +164.6% | $5M | $0.33 | 8.3% | 8.5% |
| 2024 | -$7M | -36.4% | -$7M | $-0.54 | -14.5% | -13.8% |
| 2023 | -$5M | -1073.5% | -$4M | $-0.39 | -9.9% | -8.3% |
| 2022 | $548,000 | +51.4% | $607,000 | $0.04 | 1.1% | 1.2% |
| 2021 | $362,000 | +117.3% | $366,000 | $0.02 | 0.9% | 0.9% |
| 2020 | -$2M | -1735.2% | -$2M | $-0.18 | -6.5% | -4.9% |
| 2019 | $128,000 | +108.7% | $270,000 | $0.01 | 0.5% | 1.0% |
| 2018 | -$1M | +78.6% | -$1M | $-0.13 | -7.3% | -6.7% |
| 2017 | -$7M | +34.1% | -$7M | $-0.63 | -44.7% | -44.2% |
| 2016 | -$10M | +20.5% | -$10M | $-1.20 | -93.4% | -92.3% |
| 2015 | -$13M | -77.4% | -$13M | $-1.51 | -148.3% | -149.4% |
| 2014 | -$7M | -17.0% | -$6M | $-1.32 | -64.1% | -54.2% |
| 2013 | -$6M | +26.9% | -$6M | $-2.17 | -76.1% | -74.7% |
| 2012 | -$9M | -127.8% | -$9M | $-2.22 | -121.1% | -126.8% |
| 2011 | -$4M | -30.1% | -$5M | $-1.35 | -55.2% | -76.1% |
| 2010 | -$3M | -30.4% | -$3M | $-1.04 | -59.7% | -59.8% |
| 2009 | -$2M | -445.5% | -$2M | $-0.81 | -60.4% | -62.8% |
| 2008 | $-411,000 | -141.7% | $-439,943 | $-0.12 | -29.4% | -31.4% |
| 2007 | $-170,058 | +44.0% | $-170,058 | $-0.10 | - | - |
| 2006 | $-303,718 | -23.2% | $-144,117 | $-0.12 | - | - |
| 2005 | $-246,544 | -128.9% | $-105,478 | $-0.22 | -13.7% | -5.9% |
| 2004 | $-107,687 | +26.2% | $-107,687 | $-0.15 | -5.4% | -5.4% |
| 2003 | $-145,994 | +0.9% | $-145,994 | $-0.24 | -7.3% | -7.3% |
| 2002 | $-147,312 | +78.2% | $-147,312 | $-0.24 | -6.9% | -6.9% |
| 2001 | $-676,883 | -1414.0% | $-468,931 | $-1.08 | -30.6% | -21.2% |
| 2000 | $51,512 | +157.6% | $15,022 | $0.01 | 2.4% | 0.7% |
| 1999 | $20,000 | -94.4% | $20,000 | $0.03 | 0.9% | 0.9% |
| 1998 | $360,000 | +24.1% | $70,000 | $0.49 | 15.5% | 3.0% |
| 1997 | $290,000 | +480.0% | $70,000 | $0.39 | 13.4% | 3.2% |
| 1996 | $50,000 | - | $50,000 | $0.07 | 2.3% | 2.3% |
Download Data
Export CSBR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
What is CSBR earnings per share (EPS)?
CSBR trailing twelve-month (TTM) diluted EPS is $-0.16, reflecting +161.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1996 to 2025 is available in the table on this page.
What is Champions Oncology, Inc.'s net income?
Champions Oncology, Inc. (CSBR) trailing twelve-month net income is $-2M as of 2025. Earnings grew +161.1% year-over-year.
Is CSBR profitable?
CSBR is not currently profitable on a TTM basis, reporting a net loss of $-2M. Net margin is +8.3%. Investors should monitor for a return to profitability.
What is CSBR's earnings growth rate?
CSBR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: +104.3%, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1996 to 2025.
What are CSBR's profit margins?
Champions Oncology, Inc. net profit margin is +8.3%, operating margin is +8.5%, and gross margin is +47.3%. Margins are within a typical range for the sector. Return on Equity is +503.0%.
Is CSBR growing earnings?
Yes, CSBR earnings are accelerating — EPS growth of +161.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-2M. Earnings momentum is strengthening.
What was CSBR's best earnings year?
Champions Oncology, Inc.'s highest annual net income on record is $5M, achieved in fiscal year 2025. Earnings history on this page spans 1996 to 2025 and includes all annual and quarterly figures.
What were CSBR's earnings last quarter?
CSBR's most recent reported quarter was Q3 2026. Net income was $-279000.00 with diluted EPS of $-0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.